CELLULAR BIOMEDICINE GROUP, INC. (CBMG) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Resignation of Guotong Xu

Effective November 11, 2016, Professor Guotong Xu resigned as a
director of Cellular Biomedicine Group, Inc. (the “Company”).

Prior to his resignation, Professor Xu was a Class II director of
the Company and also served on the Companys Compensation
Committee. There were no disagreements between the Company and
Professor Xu on any matter relating to the Companys operation,
policies or practices that led to his decision to resign.

To advance the Companys ongoing research programs and pipeline of
therapies, on November 11, 2016, the Board appointed Professor Xu
to the Companys Scientific Advisory Committee to lead the
continued efforts of the Companys stem cell platforms.

Appointment of Gang (Jacky) Ji

Effective November 11, 2016, the Board elected Gang (Jacky) Ji as
a non-executive Class II director of the Company and a member of
the Companys Compensation Committee.

Mr. Ji has sixteen years of experience in finance and investment.
He has been serving as Vice President of Ant Financial since
January 2016 responsible for global strategic investments of Ant
Financial. Before joining Ant Financial, he served Alibaba Group
as Vice President responsible for strategic investment for seven
years. Prior to joining Alibaba, Mr. Ji worked for several
venture capital funds and also served as an auditor of KPMG. He
currently serves as a director of Asia Game Technology Ltd., a
company listed on the Hong Kong Stock Exchange (HKEX: 8279) as
well as several private technology companies. Mr. Ji holds a
bachelors degree in international business management from
University of International Business and Economics (Beijing).

In connection with Mr. Jis appointment, the Company entered into
a letter agreement (the Agreement), the terms of which became
effective on November 11, 2016. to the Agreement, Mr. Ji is
entitled to an annual compensation of $76,000. 30% of such
compensation shall be paid in cash, payable monthly, and 70% of
such compensation will be paid in the form of a non-qualified
stock option (the Option) to purchase shares of the Companys
common stock, par value $0.001 (the Common Stock), under the
Companys 2014 equity incentive plan. On November 11, 2016, Mr. Ji
was initially granted a non-qualified option to purchase 3,620
shares of Common Stock at an exercise price of $14.70 per share,
which options shall vest in full on June 2, 2017, the date of the
Company’s 2017 annual meeting of stockholders (the AGM).
Conditioned upon Mr. Jis continuous service on the Board and the
Compensation Committee, all subsequent option grants to Mr. Ji
for the applicable equity portion of his annual compensation will
occur on the date of each AGM, with an exercise price per share
that equals to the closing price of Common Stock on the date of
grant and full vesting on the date of the next AGM following such
grant.

No family relationships exist between Mr. Ji and any of the
Company’s other directors or executive officers. There are no
arrangements between Mr. Ji and any other person to which Mr. Ji
was nominated as a director. There are no transactions to which
the Company is or was a participant and in which Mr. Ji has a
material interest subject to disclosure under Item 404(a) of
Regulation S-K.

A copy of the Agreement with Mr. Ji and the press release
announcing Mr. Jis appointment are attached hereto as Exhibit
99.1 and Exhibit 99.2.

Item 9.01.Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.		Description
99.1		Letter Agreement, dated November 11, 2016, by and between the Company and Gang Ji
99.2		Press Release, dated November 11, 2016